Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator

https://doi.org/10.1016/j.amjcard.2020.12.033Get rights and content

Low systolic blood pressure (SBP) was previously suggested to be a marker for heart failure and mortality in patients with low left ventricular ejection fraction. We aimed to explore the association of SBP on risk of ventricular tachyarrhythmias (VTA) and atrial arrhythmias as well as appropriate and inappropriate Implantable Cardioverter Defibrillator (ICD) therapy. The study population comprised 1,481 of 1,500 (99%) patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate Therapy trial. Multivariate Cox proportional hazards regression modeling was used to identify the association of baseline SBP (recorded prior to ICD implantation) with the risk of VTA > 170 beats/min during follow-up (primary end point) and atrial arrhythmia, appropriate and inappropriate ICD therapy, hospitalization and death (secondary end points). SBP was dichotomized at 120 mm Hg (approximate mean and median) and was also assessed as a continuous measure. Multivariate analysis showed that each 10 mm Hg decrement in SBP was associated with corresponding 11% increased risk for VTA (p = 0.008). Low SBP (≤120 mm Hg) was associated with a significant 58% (p = 0.002) increased risk for VTA ≥170 beats/min; 53% (p = 0.019) increased risk for VTA ≥200 beats/min; and 65% (p = 0.001) increased risk for appropriate ICD therapy, as compared with SBP >120 mm Hg. Low SBP was not associated with increased risk of atrial arrhythmias, and inappropriate ICD therapy. In conclusion, in MADIT-RIT, SBP (≤120 mm Hg) predicted higher rates of VTA. These findings suggest that SBP may be utilized for VTA risk stratification in candidates for primary ICD therapy.

Section snippets

Methods

MADIT-RIT was a multicenter, randomized, prospective, controlled clinical trial evaluating patients with approved indications for primary prevention ICD or CRT therapy. The trial design and results have been published elsewhere.6 Briefly, patients were randomized to standard ICD programming (arm A), a high-rate therapy cutoff (≥200 beats/min) programming strategy (arm B), or a prolonged detection duration (60-second delay for ventricular tachycardia [VT] zone 170–199 beats/min, 12-second delay

Results

The distribution of SBP in study patients is presented in Figure 1, showing a normal distribution with a mean SBP of 123 ± 19 mm Hg and a median of 121 mm Hg (IQ range 96 to 146). Among 1481 study patients, 727 (49%) patients had lower SBP and 754 (51%) had higher SBP. Relevant baseline clinical characteristics of patients with SBP≤120 mm Hg and SBP >120 mm Hg are shown in Table 1. Patients with SBP≤120 mm Hg were younger, were less likely to have diabetes mellitus and had a lower LVEF. They

Discussion

The main finding of this study is that patients with indication for ICD or CRT-D implantation and with lower SBP at baseline (≤120 mm Hg) are at greater risk for ventricular tachyarrhythmia compared with those with higher baseline SBP.

Elevated SBP has been described a surrogate marker for VTA events in large population studies1,3,9 and in patients with HF, albeit with preserved ejection fraction (EF).10 There are many mechanistic explanations for these finding. A possible common pathway in

Credit Author Statement

Eyal Nof, Roy Beinart, Ilan Goldenberg:Conceptualization, Methodology, Writing- Original draft preparation; Arwa Younis, David Huang, Mehmet K. Aktas , Rosero Spencer and Valentina Kutyifa: Methodology , Visualization, Investigation. Scott McNitt: Statistical Ananlysis

Disclosures

The authors declare that they have no known competing financial interests or personal relations that could have appeared to influence the work reported in this study.

Cited by (0)

Dr. Valentina Kutyifa has received Research grants were came from Boston Scientific HQ 300 Boston Scientific Way Marlborough, MA 01752-1234. Zoll HQ: 269 Mill Road Chelmsford, MA 01824-4105 U.S.A. Medtronic: 710 Medtronic Parkway Minneapolis, MN 55432-5604 USA. Mirowski Foundation: Chestnut Hill Massachusetts, USA.

View full text